]. These three articles highlight the current intense interest in these subjects. The issues are not, however, without controversy.
To adequately discuss the issue of ultrasensitivity, it is necessary to define a few pertinent terms and briefly review the clinical scenarios where PSA determinations in the ultrasensitive range may have clinical value. Although there is no agreed-upon definition of an ultrasensitive PSA assay, those who have previously addressed this subject have focused on immunodiagnostic assays with a biological detection limit for PSA of <0.1 gfL (4) (5) (6) (7) (8) (9) . The two articles on ultrasensitive PSA assays in this issue conform to that de facto standard. The term "biological detection limit" may be unfamiliar to many readers but was introduced by us in our initial description of the standard Hybritech Tandem-R PSA Because PSA is a serine protease, the enzymatically active form binds to inhibitors in serum, forming complexes. One such inhibitor is a-macroglobulin, which is thought to engulf PSA, rendering it undetectable by current immunoassays. A second inhibitor is a1-antichymotrypsin, which binds to PSA to form acornplex of -90 kDa (PSA-ACT). This complex is detected by PSA immunoassay.
Serum also contains unbound PSA (free PSA), the nature of which is not fully understood, but may represent the zymogen or other enzymatically inactive form. Free PSA is also detected by PSA immunoassay. Thus, for the purpose of discussion here, PSA-ACT and free PSA are considered to constitute the total immunoreactive fraction that is detected by standard PSA immunoassay (total PSA), with PSA-ACT representing the major portion.
For reasons that remain elusive, the percentage of PSA-ACT may be higher in patients with prostate cancer than in patients with BPH or normal controls. This 
ACT/total
PSA ratio approach has been tested in a prospective screening population.
Such studies are critical and, we hope, will soon be forthcoming.
In the US, the cutoff in early detection protocols has been 4 /LgIL, not 7.5 pg/L or higher, as used by Leinonen Until then, differences among assays, including calibrator design, antibody specificity and affinity, and format will complicate the assessment of cmical utility and comparisons among assays. Some specimen discrepancies encountered between assays may reflect the fact that the PSA assays in current use are not necessarily equimolar in their ability to detect free PSA and the PSA-ACT forms (30). Should the ratio in forms shift, differences between the measurement modes (e.g., kinetic vs equilibrium) or in any one of several aspects of calibrator design could result in noticeable variances in the reported concentration of total PSA in that specimen.
This further underscores the cautionary use of data generated by PSA immunoassays that have not been fully validated through appropriate clinical trials.
